Post Operative Pain Control of POEM Procedure

Sponsor
Chen Wannan (Other)
Overall Status
Unknown status
CT.gov ID
NCT04177342
Collaborator
(none)
196
2
17.9

Study Details

Study Description

Brief Summary

Peroral endoscopic myotomy (POEM) is a minimally invasive treatment for esophageal achalasia with a natural orifice transluminal endoscopic procedure and far less invasive than the standard surgical or laparoscopic Heller myotomy (LHM). Less is known about the postoperative pain after POEM and the minor surgery trauma, short length of stay may lead to underestimation of postoperative pain control. We tend to observe the pain status after the POEM surgery under the empirical treatment in our center, and find a proper intra-operative way of pain control to solve the post-operative pain and seek the possible influence factors of postoperative pain.

Condition or Disease Intervention/Treatment Phase
Phase 4

Study Design

Study Type:
Interventional
Anticipated Enrollment :
196 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
patients will be devided randomly into two groups. One group will be given oxycodone and the other will be given fentanyl during the POEM procedure. Post procedure pain condition will be recorded.patients will be devided randomly into two groups. One group will be given oxycodone and the other will be given fentanyl during the POEM procedure. Post procedure pain condition will be recorded.
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
Influence of Intraoperative Opioids (Oxycodone/Fentanyl) Usage on the Post-operative Pain Management of Peroral Endoscopic Myotomy (POEM)
Anticipated Study Start Date :
Jan 1, 2020
Anticipated Primary Completion Date :
Dec 31, 2020
Anticipated Study Completion Date :
Jun 30, 2021

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: fentanyl

the patients use remifentanil and fentanyl as intra-operatively pain control and compare the post-operative pain condition with the oxycodone group

Drug: Fentanyl
the patients use remifentanil and fentanyl as intra-operatively pain control and compare the post-operative pain condition with the oxycodone group

Experimental: oxycodone

the patients use oxycodone and remifentanil as intra-operatively pain control and compare the post-operative pain condition with the fentanyl group

Drug: Oxycodone
the patients use oxycodone and remifentanil as intra-operatively pain control and compare the post-operative pain condition with the fentanyl group

Outcome Measures

Primary Outcome Measures

  1. post-operative pain condition [36 hours after the POEM surgery]

    use Visual Analogue Scale/Score(0-10) to record post operative pain

  2. post-operative PCA usage volumn [36 hours after the POEM surgery]

    record PCA usage volumn(ml) to see the dosage of opiods used after the surgery

  3. post-operative sleep quality [48 hoursafter the surgery]

    Postoperative sleep quality was investigated with a self-reported sleep questionnaire including 6 yes/no questions(0-6) with full score 6 represented the worst sleep

Secondary Outcome Measures

  1. chronic pain condition [28 days after discharge]

    use Visual Analogue Scale/Score(0-10) to evaluate the pain condition

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Achalasia patients undergoing elective POEM surgery

  • age 18-80

  • BMI 18-30 kg/m2

Exclusion Criteria:
  • Patient refusal

  • ASA≥ 3

  • abnormality of liver and kidney function in patients

  • patients with mental disorder, language disorder, and other patients who can not cooperate with and complete the follow-up and questionnaire pre- and post- operatively

  • patients (including propanotamo, propofol, lidocaine, and other drugs) against drug taboos in the anesthetic scheme

  • patients with chronic pain before operation with analgesic drugs

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Chen Wannan

Investigators

  • Principal Investigator: Wannan Chen, MD, Shanhai Zhongshan

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Chen Wannan, Principal Investigator, Shanghai Zhongshan Hospital
ClinicalTrials.gov Identifier:
NCT04177342
Other Study ID Numbers:
  • POEM pain control
First Posted:
Nov 26, 2019
Last Update Posted:
Nov 26, 2019
Last Verified:
Nov 1, 2019
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Chen Wannan, Principal Investigator, Shanghai Zhongshan Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 26, 2019